Douglas Unwin, president and CEO of Pacific Therapeutics, has announced that his company has finalized a definitive agreement to license an approved drug to treat erectile dysfunction. The drug will utilize an oral dissolving technology (sublingual formulation), which improves upon existing erectile dysfunction drugs by being faster acting and with fewer side effects. Pacific Therapeutics plan on moving the drug through trials and obtaining regulatory approval within the next year, with late stage clinical trials and marketing following within the next two years.<\/p>\n
The Hard Facts About The ED Market<\/strong><\/p>\n It is estimated that over 150 men worldwide suffer from erectile dysfunction. Additionally, it is estimated that more than 20 million North American men have experienced some degree of erection issues at some point. \u00a0Furthermore, it is estimated that more than 85%-90% of all cases of erection problems goes undiagnosed. With so many potential buyers, companies have been jockeying for a chance to break into the lucrative erectile dysfunction market. Total sales of erectile dysfunction drugs in 2006 topped $3.1 billion, with the number growing to more than $5 billion by 2011.<\/p>\n Despite this, there are very few oral dissolving erectile dysfunction drugs on the market. Viagra, Cialis, and Levitra have cornered the market, while new drug Stendra was recently approved for distribution. The Food and Drug Administration sets strict guidelines for erectile dysfunction medication, making it difficult for companies to get their drug onto the market. In fact, until Stendra’s approval, the Food and Drug Administration hadn’t approved any new erectile dysfunction drugs in ten years. Pacific Therapeutics is optimistic that it’s drug will make it to the market, and will could help millions of men afflicted with erectile dysfunction.<\/p>\n","protected":false},"excerpt":{"rendered":" Douglas Unwin, president and CEO of Pacific Therapeutics, has announced that his company has finalized a definitive agreement to license an approved drug to treat erectile dysfunction. The drug will utilize an oral dissolving technology (sublingual formulation), which improves upon existing erectile dysfunction drugs by being faster acting and with fewer side effects. Pacific Therapeutics […]<\/p>\n","protected":false},"author":5,"featured_media":4378,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_autoblog_aioseo_focus_keyphrase":"","_autoblog_aioseo_title":"","_autoblog_aioseo_description":"","footnotes":""},"categories":[20],"tags":[],"class_list":["post-4376","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-erectile-dysfunction"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t